50.85
-4.62 (-8.33%)
| Previous Close | 55.47 |
| Open | 55.27 |
| Volume | 1,436,810 |
| Avg. Volume (3M) | 738,917 |
| Market Cap | 3,764,257,792 |
| Price / Sales | 1.90 |
| Price / Book | 3.81 |
| 52 Weeks Range | |
| Earnings Date | 6 May 2025 - 12 May 2025 |
| Profit Margin | 0.15% |
| Operating Margin (TTM) | 6.23% |
| Diluted EPS (TTM) | 0.040 |
| Quarterly Revenue Growth (YOY) | 13.50% |
| Quarterly Earnings Growth (YOY) | -81.70% |
| Total Debt/Equity (MRQ) | 152.54% |
| Current Ratio (MRQ) | 2.12 |
| Operating Cash Flow (TTM) | 233.02 M |
| Levered Free Cash Flow (TTM) | 51.06 M |
| Return on Assets (TTM) | 2.35% |
| Return on Equity (TTM) | 3.99% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Mixed |
| Diagnostics & Research (Global) | Mixed | Mixed | |
| Stock | RadNet, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | -5.0 |
| Price Volatility | 4.5 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | -4.0 |
| Average | 0.00 |
|
RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments; The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures, and Artificial Intelligence segment develops and deploys clinical applications to enhance interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics. The company derives a majority of its revenue from the Imaging center segment. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Growth |
| % Held by Insiders | 10.43% |
| % Held by Institutions | 88.77% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 88.00 (Truist Securities, 73.06%) | Buy |
| Median | 72.50 (42.58%) | |
| Low | 60.00 (Barclays, 17.99%) | Buy |
| Average | 73.25 (44.05%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 57.60 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Barclays | 24 Mar 2025 | 60.00 (17.99%) | Buy | 51.83 |
| 22 Jan 2025 | 74.00 (45.53%) | Buy | 63.73 | |
| Raymond James | 05 Mar 2025 | 65.00 (27.83%) | Buy | 53.09 |
| Truist Securities | 22 Jan 2025 | 88.00 (73.06%) | Buy | 63.73 |
| Jefferies | 15 Jan 2025 | 80.00 (57.33%) | Buy | 61.74 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 27 Feb 2025 | Announcement | RadNet Reports Fourth Quarter 2024 Results, Including Record Revenue and Adjusted EBITDA(1) and Releases 2025 Financial Guidance |
| 26 Feb 2025 | Announcement | RadNet and OB/GYN Specialists of the Palm Beaches Enhance Breast Cancer Screening with State-of-the-Art Imaging Services |
| 26 Feb 2025 | Announcement | DeepHealth Introduces New AI-Powered Radiology Informatics and Population Screening Solutions at #ECR2025 |
| 25 Feb 2025 | Announcement | RadNet’s Wholly-Owned Subsidiary, DeepHealth, and ConcertAI’s TeraRecon Announce Strategic Collaboration Around Integrated AI and Advanced Visualization |
| 14 Feb 2025 | Announcement | RadNet, Inc. Announces Date of its Fourth Quarter 2024 Financial Results Conference Call |
| 08 Jan 2025 | Announcement | RadNet, Inc. to Present at the 43rd Annual J.P. Morgan Healthcare Conference January 15th, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |